	Application No.	Applicant(s)
Notice of Allowability	10/086,176	HEMBROUGH ET AL.
	Examiner	Art Unit
	Michael Borin	1631
	Wildriget Boriti	1031
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>09/20/2004 and 03/02/2005</u> .		
2. The allowed claim(s) is/are <u>1-18</u> .		
3. The drawings filed on 28 February 2002 are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this patients store explication from the 		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)). * Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	 5. Notice of Informal Patent Application (PTO-152) 6. Interview Summary (PTO-413), Paper No./Mail Date
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date		
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material Output Date	8. Examiner's Stateme 9. Other	nt of Reasons for Allowance

Application/Control Number: 10/086,176

Art Unit: 1631

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Sima S. Kulkarni on 03/01/2005.

The application has been amended as follows:

Claim 1: at the end of claim, replace "." with --, wherein the C-terminal peptide comprises at least 23 C-terminal residues of SEQ ID No. 5 or SEQ ID No. 6. --

Claim 2: replace "is" with - occurs during -

Claim 5, line 2: remove "or peptide"

Claim 5, lines 2-3: remove "a homolog thereof, or anti-proliferative fragment thereof"

Claim 6: replace "anti-proliferative fragment" with -- C-terminal peptide --

Claim 7: replace "anti-proliferative fragment" with -- C-terminal peptide --

Claim 8, line 2: remove "or peptide"

Application/Control Number: 10/086,176

Art Unit: 1631

Claim 8, lines 2-3: remove "a homolog thereof, or anti-proliferative fragment thereof"

Claim 9: replace "anti-proliferative fragment" with -- C-terminal peptide --

Claim 11: at the end of claim, replace "." with --, wherein the C-terminal peptide comprises at least 23 C-terminal residues of SEQ ID No. 5 or SEQ ID No. 6. --

Claim 13, line 2: remove "or peptide"

Claim 13, lines 2-3: remove "a homolog thereof, or anti-proliferative fragment thereof"

Claim 14: replace "anti-proliferative fragment" with -- C-terminal peptide --

Claim 15: replace "anti-proliferative fragment" with -- C-terminal peptide --

Claim 16, line 2: remove "or peptide"

Claim 16, lines 2-3: remove "a homolog thereof, or anti-proliferative fragment thereof"

Claim 17: replace claim with:

-- The method of claim 11 wherein the C-terminal peptide consists of SEQ ID No. 4. --

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Borin whose telephone number is (571) 272-0713. The examiner can normally be reached on 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, Ph.D., can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael Borin, Ph.D.
Primary Examiner
Art Unit 1631

mlb